Levetiracetam targets DMG’s growth drivers, boosting survival in a tumor subclass
TL;DR
Retrospective data from multiple centers show levetiracetam use is linked to longer overall survival in pediatric diffuse midline glioma (DMG) but not in hemispheric high-grade gliomas. In DMG models, levetiracetam reduces tumor growth and extends survival by selectively dampening low-frequency GABAergic neuron-to-glioma synaptic transmission through a brain-tumor–specific, SV2A-independent mechanism; brivaracetam (SV2A-targeted) did not reproduce this effect. The findings suggest a DMG-specific therapeutic avenue that warrants prospective trials, with caveats including small sample sizes and retrospective design.
Topics:healthmedicine#diffuse-midline-glioma#gabaergic-synapses#levetiracetam#medicine#neuron-glioma-interactions#pediatric-glioma
- Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma Nature
- Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows Stanford Medicine
- Seizure Medication Linked to Longer Survival in Diffuse Midline Glioma Cure Today
- Common Seizure Drug Levetiracetam Slowed Deadly Childhood Brain Tumors in Lab Models and Was Tied to Longer Survival medicaldaily.com
- Anti-Seizure Drug Could Slow Aggressive Childhood Brain Tumors insideprecisionmedicine.com
Want the full story? Read the original reporting
Read on Nature